共 242 条
[11]
Río FG(2016)A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD Int J Chron Obstruct Pulmon Dis 11 971-486
[12]
Martínez J(2014)Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials Lancet Respir Med 2 472-74
[13]
Masa J(2016)Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trials Respir Med 112 65-1760
[14]
Sobradillo V(2014)Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial Respir Med 108 1752-755
[15]
Villasante C(2017)Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study Int J Chron Obstruct Pulmon Dis 12 745-881
[16]
Jiménez-Ruiz C(2015)Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations Respir Med 109 870-1196
[17]
Fernández-Fau L(2015)Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial Pulm Med 15 91-316
[18]
Viejo J(2017)Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis Respir Res 18 196-2533
[19]
Miravitlles M(2016)A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD Chest 149 1181-946
[20]
Murio C(2017)A network meta-analysis of long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) combinations in COPD Pulm Ther 3 297-480